You have read all your free articles, to continue reading subscribe to read the rest of this content.
Spago Nanomedical has received regulatory approval to initiate a Phase IIa clinical study with its MRI contrast agent SN132D in endometriosis. Patient recruitment has started, and the first patient is expected to be dosed shortly. The ongoing SPAGOPIX-01 study in breast cancer has now been concluAlready a subscriber Login You…
Promore Pharma and Cellastra, a clinical stage developer of pharmaceutical assets, has announced the signing of a term sheet, towards a strategic collaboration for the Phase III clinical development of PXL01 and subsequent registration and marketing in the US and Canada. "This co-development initAlready a subscriber Login You have read…
BioInvent International has announced treatment of the first patient in a Phase 1/2a trial of its second anti-FcyRIIB antibody BI-1607 in combination with trastuzumab in HER2+ solid tumors. The first-in-human Phase 1 trial is a dose escalation study of BI-1607 combined with trastuzumab in HER2+ aAlready a subscriber Login You…
The first child has been vaccinated in The Gambia with the company's ETEC vaccine candidate, ETVAX. It is a randomised, placebo-controlled, and double-blind phase IIB study. The study will include about 5,000 children aged 6-23 months. The overall goal of the study is to investigate the protectivAlready a subscriber Login…
